Karyopharm Therapeutics Inc.

NasdaqGS:KPTI Stock Report

Market Cap: US$131.6m

Karyopharm Therapeutics Balance Sheet Health

Financial Health criteria checks 2/6

Karyopharm Therapeutics has a total shareholder equity of $-136.2M and total debt of $303.4M, which brings its debt-to-equity ratio to -222.7%. Its total assets and total liabilities are $240.4M and $376.6M respectively.

Key information

-222.7%

Debt to equity ratio

US$303.40m

Debt

Interest coverage ration/a
CashUS$191.44m
Equity-US$136.21m
Total liabilitiesUS$376.64m
Total assetsUS$240.44m

Recent financial health updates

Recent updates

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Feb 23
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 33%

Karyopharm: Approaching The Bottom Ahead Of Earnings And Topline Data (Rating Upgrade)

Feb 05

Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Apr 17
Improved Revenues Required Before Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Stock's 27% Jump Looks Justified

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Apr 17
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Surges 27% Yet Its Low P/S Is No Reason For Excitement

Karyopharm: Market Is Overlooking Growth

Oct 07

Karyopharm Therapeutics Q2 2022 Earnings Preview

Aug 03

Karyopharm cancer therapy eltanexor gets FDA fast track status, orphan drug tag in EU

Jul 20

Karyopharm: Another 2 Year Wait For Data

May 05

Karyopharm: Opportunity To Buy Based On Latest Endometrial Cancer Data And Xpovio Sales Estimates

Feb 19

Karyopharm Therapeutics: Unjustified Sell-Off Provides An Opportunity To Reload My Position

Dec 04

Karyopharm Therapeutics: After Years Of Waiting I'm Ready To Join The Bulls

Sep 16

Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Aug 07
Analyst Forecasts Just Became More Bearish On Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Financial Position Analysis

Short Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: KPTI has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: KPTI has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: KPTI's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: KPTI has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: KPTI has sufficient cash runway for 1.9 years if free cash flow continues to grow at historical rates of 3.8% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.